Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France
Sponsor
AstraZeneca (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT01238809
Collaborator
(none)
7,300
30
Study Details
Study Description
Brief Summary
The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
7300 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France
Study Start Date
:
Jun 1, 2011
Anticipated Primary Completion Date
:
Jul 1, 2011
Anticipated Study Completion Date
:
Jul 1, 2011
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 1
|
Outcome Measures
Primary Outcome Measures
- low-dose aspirin and gastroprotective treatment compliance (Girerd questionnaire: a 6-item self-administered and validated questionnaire to evaluate adherence to treatments) [One month]
Eligibility Criteria
Criteria
Ages Eligible for Study:
60 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- French people > 60 years old, part of Kantar Health Access Sant� panel
Exclusion Criteria: -
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AstraZeneca
Investigators
- Principal Investigator: Mrs Genevieve BONNELYE, KantarHealth - France
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT01238809
Other Study ID Numbers:
- NIS-CFR-DUM-2010/1
First Posted:
Nov 11, 2010
Last Update Posted:
Jun 8, 2011
Last Verified:
Jun 1, 2011